Kazia Therapeutics Ltd
Kazia Therapeutics Ltd (ASX:KZA) is listed on the Australian Securities Exchange.
See more information about Kazia Therapeutics Ltd
Kazia Therapeutics raises $1.8 million in well supported share placement
Kazia Therapeutics Ltd (ASX:KZA) has raised $1.8 million through a share purchase plan (SPP) to eligible shareholders in Australia and New Zealand and this follows a $7.2 million institutional placement.
The SPP offered shareholders the opportunity to apply for up to $30,000 worth of shares in Kazia, without incurring brokerage or other transaction costs.
Shares were offered at a price of 40 cents per share, which was equal to the price under the institutional placement announced on April 8 which raised approximately $7.2 million.
Funds from the placements will be used to progress the paxalisib clinical trial program and to complete analysis of the ongoing Phase I study of Cantrixil, to continue to provide contributory funding towards four other trials and as working capital for the company.
Proceeds to "enrich" R&D programs
Chairman Iain Ross said: "Following our successful institutional placement in early April, the board considered it imperative that existing shareholders have the opportunity to augment their holdings in the company at the same price as the institutional investors.
"We are delighted to have received a very high level of engagement with this SPP.
"As on previous occasions, the proceeds will be applied directly to progressing and enriching the company's R&D programs.
"We expect paxalisib to transition to a pivotal study in the second half of this year, so it is a particularly critical time for the company.
"We are, as always, grateful for the strong and enthusiastic support of our shareholders and look forward to sharing further progress as the year advances."
Other Kazia Therapeutics Ltd news
- Kazia Therapeutics to collaborate with Dana-Farber Cancer Institute in paxalisib clinical trial for primary CNS lymphoma
2020-09-22 - Kazia Therapeutics bringing a vetted drug class to the brain: Edison
2020-09-09 - Kazia Therapeutics awarded US FDA Orphan Drug Designation to paxalisib treatment for malignant glioma
2020-08-24 - Kazia Therapeutics extends SPP owing to strong demand
2020-05-04 - Kazia Therapeutics substantial holder increases position
2020-03-19
